Genomic evolution from primary breast carcinoma to distant metastasis: Few copy number changes of breast cancer related genes

Cancer Letters

Volumn 344, Issue 1, 2014, Pages 138-146

  Moelans, Cathy B ^a   van der Groep, Petra ^a   Hoefnagel, Laurien D C ^a   van de Vijver, Marc J ^b   Wesseling, Pieter ^c,d,e   Wesseling, Jelle ^f   van der Wall, Elsken ^a   van Diest, Paul J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^f NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Breast cancer; Gene dosage; Metastases; MLPA

Indexed keywords

TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 4; UVOMORULIN;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; BREAST CARCINOMA; COPY NUMBER VARIATION; CYCLIN E1 GENE; DISTANT METASTASIS; E CADHERIN GENE; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MEDIATOR SUBUNIT 1 GENE; METADHERIN GENE; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; ONCOGENE; PRDM14 GENE; PRIORITY JOURNAL; SKIN METASTASIS; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 4 GENE; TUMOR SUPPRESSOR GENE;

BREAST CANCER; GENE DOSAGE; METASTASES; MLPA;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; GENE DOSAGE; GENES, TUMOR SUPPRESSOR; GENOMICS; HUMANS; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; ONCOGENES;

EID: 84893696572     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.10.025     Document Type: Article

References (50)

1. Rabbani S.A., Mazar A.P. Evaluating distant metastases in breast cancer: from biology to outcomes. Cancer Metastasis Rev. 2007, 26:663-674.
2. Fidler I.J., Kripke M.L. Metastasis results from preexisting variant cells within a malignant tumor. Science 1977, 197:893-895.
3. Poste G., Fidler I.J. The pathogenesis of cancer metastasis. Nature 1980, 283:139-146.
4. Price J.E., Carr D., Tarin D. Spontaneous and induced metastasis of naturally occurring tumors in mice: analysis of cell shedding into the blood. J. Natl. Cancer Inst. 1984, 73:1319-1326.
5. Fidler I.J., Hart I.R. Biological diversity in metastatic neoplasms: origins and implications. Science 1982, 217:998-1003.
6. Giavazzi R., Alessandri G., Spreafico F., Garattini S., Mantovani A. Metastasizing capacity of tumour cells from spontaneous metastases of transplanted murine tumours. Br. J. Cancer 1980, 42:462-472.
7. Vaage J. Metastasizing potentials of mouse mammary tumors and their metastases. Int. J. Cancer 1988, 41:855-858.
8. Weigelt B., Glas A.M., Wessels L.F., Witteveen A.T., Peterse J.L., van't Veer L.J. Gene expression profiles of primary breast tumors maintained in distant metastases. Proc. Natl. Acad. Sci. USA 2003, 100:15901-15905.
9. Nishizaki T., DeVries S., Chew K., Goodson W.H., Ljung B.M., Thor A., Waldman F.M. Genetic alterations in primary breast cancers and their metastases: direct comparison using modified comparative genomic hybridization. Genes Chromosomes. Cancer 1997, 19:267-272.
10. Wikman H., Lamszus K., Detels N., Uslar L., Wrage M., Benner C., Hohensee I., Ylstra B., Eylmann K., Zapatka M., Sauter G., Kemming D., Glatzel M., Muller V., Westphal M., Pantel K. Relevance of PTEN loss in brain metastasis formation in breast cancer patients. Breast Cancer Res. 2012, 14:R49.
11. Minn A.J., Gupta G.P., Siegel P.M., Bos P.D., Shu W., Giri D.D., Viale A., Olshen A.B., Gerald W.L., Massague J. Genes that mediate breast cancer metastasis to lung. Nature 2005, 436:518-524.
12. Kang Y., Siegel P.M., Shu W., Drobnjak M., Kakonen S.M., Cordon-Cardo C., Guise T.A., Massague J. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003, 3:537-549.
13. Wang Y., Klijn J.G., Zhang Y., Sieuwerts A.M., Look M.P., Yang F., Talantov D., Timmermans M., Meijer-van Gelder M.E., Yu J., Jatkoe T., Berns E.M., Atkins D., Foekens J.A. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365:671-679.
14. van't Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M., Peterse H.L., van der K.K., Marton M.J., Witteveen A.T., Schreiber G.J., Kerkhoven R.M., Roberts C., Linsley P.S., Bernards R., Friend S.H. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
15. Ding L., Ellis M.J., Li S., Larson D.E., Chen K., Wallis J.W., Harris C.C., McLellan M.D., Fulton R.S., Fulton L.L., Abbott R.M., Hoog J., Dooling D.J., Koboldt D.C., Schmidt H., Kalicki J., Zhang Q., Chen L., Lin L., Wendl M.C., McMichael J.F., Magrini V.J., Cook L., McGrath S.D., Vickery T.L., Appelbaum E., Deschryver K., Davies S., Guintoli T., Lin L., Crowder R., Tao Y., Snider J.E., Smith S.M., Dukes A.F., Sanderson G.E., Pohl C.S., Delehaunty K.D., Fronick C.C., Pape K.A., Reed J.S., Robinson J.S., Hodges J.S., Schierding W., Dees N.D., Shen D., Locke D.P., Wiechert M.E., Eldred J.M., Peck J.B., Oberkfell B.J., Lolofie J.T., Du F., Hawkins A.E., O'Laughlin M.D., Bernard K.E., Cunningham M., Elliott G., Mason M.D., Thompson D.M., Ivanovich J.L., Goodfellow P.J., Perou C.M., Weinstock G.M., Aft R., Watson M., Ley T.J., Wilson R.K., Mardis E.R. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010, 464:999-1005.
16. Schouten J.P., McElgunn C.J., Waaijer R., Zwijnenburg D., Diepvens F., Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 2002, 30:e57.
17. Moelans C.B., de Weger R.A., Ezendam C., van Diest P.J. HER-2/neu amplification testing in breast cancer by Multiplex Ligation-dependent probe amplification: influence of manual- and laser microdissection. BMC Cancer 2009, 9:4.
18. Moelans C.B., de Weger R.A., van Blokland M.T., Ezendam C., Elshof S., Tilanus M.G., van Diest P.J. HER-2/neu amplification testing in breast cancer by multiplex ligation-dependent probe amplification in comparison with immunohistochemistry and in situ hybridization. Cell Oncol. 2009, 31:1-10.
19. van Diest P.J. No consent should be needed for using leftover body material for scientific purposes. BMJ 2002, 325:648-651.
20. Moelans C.B., de Weger R.A., Monsuur H.N., Vijzelaar R., van Diest P.J. Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes. Mod. Pathol. 2010, 23:1029-1039.
21. Moelans C.B., de Weger R.A., van Diest P.J. Multiplex ligation-dependent probe amplification to detect HER2 amplification in breast cancer: new insights in optimal cut-off value. Cell Oncol. 2010, 32:311-312.
22. Hoefnagel L.D., van de Vijver M.J., van Slooten H.J., Wesseling P., Wesseling J., Westenend P.J., Bart J., Seldenrijk C.A., Nagtegaal I.D., Oudejans J., van der Valk P., van der Groep P., de Vries E.G., van der Wall E., van Diest P.J. Receptor conversion in distant breast cancer metastases. Breast Cancer Res. 2010, 12:R75.
23. Hoefnagel L.D., Moelans C.B., Meijer S.L., van Slooten H.J., Wesseling P., Wesseling J., Westenend P.J., Bart J., Seldenrijk C.A., Nagtegaal I.D., Oudejans J., van der Valk P., van Gils C.H., van der Wall E., van Diest P.J. Prognostic value of estrogen receptor alpha and progesterone receptor conversion in distant breast cancer metastases. Cancer 2012, 118:4929-4935.
24. Vecchi M., Confalonieri S., Nuciforo P., Vigano M.A., Capra M., Bianchi M., Nicosia D., Bianchi F., Galimberti V., Viale G., Palermo G., Riccardi A., Campanini R., Daidone M.G., Pierotti M.A., Pece S., Di Fiore P.P. Breast cancer metastases are molecularly distinct from their primary tumors. Oncogene 2008, 27:2148-2158.
25. Poplawski A.B., Jankowski M., Erickson S.W., az de S.T., Partridge E.C., Crasto C., Guo J., Gibson J., Menzel U., Bruder C.E., Kaczmarczyk A., Benetkiewicz M., Andersson R., Sandgren J., Zegarska B., Bala D., Srutek E., Allison D.B., Piotrowski A., Zegarski W., Dumanski J.P. Frequent genetic differences between matched primary and metastatic breast cancer provide an approach to identification of biomarkers for disease progression. Eur. J. Hum. Genet. 2010, 18:560-568.
26. Desouki M.M., Liao S., Conroy J., Nowak N.J., Shepherd L., Gaile D.P., Geradts J. The genomic relationship between primary breast carcinomas and their nodal metastases. Cancer Invest 2011, 29:300-307.
27. Moelans C.B., de Wegers R.A., Monsuurs H.N., Maess A.H., van Diest P.J. Molecular differences between ductal carcinoma in situ and adjacent invasive breast carcinoma: a multiplex ligation-dependent probe amplification study. Cell Oncol. (Dordr.) 2011, 34:475-482.
28. Tokunaga E., Nakashima Y., Yamashita N., Hisamatsu Y., Okada S., Akiyoshi S., Aishima S., Kitao H., Morita M., Maehara Y. Overexpression of metadherin/MTDH is associated with an aggressive phenotype and a poor prognosis in invasive breast cancer. Breast Cancer 2012.
29. Wang C., Yang Q. Astrocyte elevated gene-1 and breast cancer (Review). Oncol. Lett. 2011, 2:399-405.
30. Hu G., Chong R.A., Yang Q., Wei Y., Blanco M.A., Li F., Reiss M., Au J.L., Haffty B.G., Kang Y. MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer Cell 2009, 15:9-20.
31. Oliveira C., Sousa S., Pinheiro H., Karam R., Bordeira-Carrico R., Senz J., Kaurah P., Carvalho J., Pereira R., Gusmao L., Wen X., Cipriano M.A., Yokota J., Carneiro F., Huntsman D., Seruca R. Quantification of epigenetic and genetic 2nd hits in CDH1 during hereditary diffuse gastric cancer syndrome progression. Gastroenterology 2009, 136:2137-2148.
32. Cui J., Germer K., Wu T., Wang J., Luo J., Wang S.C., Wang Q., Zhang X. Cross-talk between HER2 and MED1 regulates tamoxifen resistance of human breast cancer cells. Cancer Res. 2012, 72:5625-5634.
33. Lamy P.J., Fina F., Bascoul-Mollevi C., Laberenne A.C., Martin P.M., Ouafik L., Jacot W. Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers. Breast Cancer Res. 2011, 13:R15.
34. Nishikawa N., Toyota M., Suzuki H., Honma T., Fujikane T., Ohmura T., Nishidate T., Ohe-Toyota M., Maruyama R., Sonoda T., Sasaki Y., Urano T., Imai K., Hirata K., Tokino T. Gene amplification and overexpression of PRDM14 in breast cancers. Cancer Res. 2007, 67:9649-9657.
35. Agarwal R., Gonzalez-Angulo A.M., Myhre S., Carey M., Lee J.S., Overgaard J., Alsner J., Stemke-Hale K., Lluch A., Neve R.M., Kuo W.L., Sorlie T., Sahin A., Valero V., Keyomarsi K., Gray J.W., Borresen-Dale A.L., Mills G.B., Hennessy B.T. Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer. Clin. Cancer Res. 2009, 15:3654-3662.
36. Sieuwerts A.M., Look M.P., Meijer-van Gelder M.E., Timmermans M., Trapman A.M., Garcia R.R., Arnold M., Goedheer A.J., de Weerd V., Portengen H., Klijn J.G., Foekens J.A. Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients. Clin. Cancer Res. 2006, 12:3319-3328.
37. Scaltriti M., Eichhorn P.J., Cortes J., Prudkin L., Aura C., Jimenez J., Chandarlapaty S., Serra V., Prat A., Ibrahim Y.H., Guzman M., Gili M., Rodriguez O., Rodriguez S., Perez J., Green S.R., Mai S., Rosen N., Hudis C., Baselga J. Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc. Natl. Acad. Sci. USA 2011, 108:3761-3766.
38. Camilleri-Broet S., Cremer I., Marmey B., Comperat E., Viguie F., Audouin J., Rio M.C., Fridman W.H., Sautes-Fridman C., Regnier C.H. TRAF4 overexpression is a common characteristic of human carcinomas. Oncogene 2007, 26:142-147.
39. Yi P., Xia W., Wu R.C., Lonard D.M., Hung M.C., O'Malley B.W. SRC-3 coactivator regulates cell resistance to cytotoxic stress via TRAF4-mediated p53 destabilization. Genes Dev. 2013, 27:274-287.
40. Valentin M.D., da Silva S.D., Privat M., aoui-Jamali M., Bignon Y.J. Molecular insights on basal-like breast cancer. Breast Cancer Res. Treat. 2012, 134:21-30.
41. Kennecke H., Yerushalmi R., Woods R., Cheang M.C., Voduc D., Speers C.H., Nielsen T.O., Gelmon K. Metastatic behavior of breast cancer subtypes. J. Clin. Oncol. 2010, 28:3271-3277.
42. Delpech Y., Coutant C., Hsu L., Barranger E., Iwamoto T., Barcenas C.H., Hortobagyi G.N., Rouzier R., Esteva F.J., Pusztai L. Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas. Br. J. Cancer 2013, 108:285-291.
43. Sihto H., Lundin J., Lundin M., Lehtimaki T., Ristimaki A., Holli K., Sailas L., Kataja V., Turpeenniemi-Hujanen T., Isola J., Heikkila P., Joensuu H. Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study. Breast Cancer Res. 2011, 13:R87.
44. Moelans C.B., Monsuur H.N., de Pinth J.H., Radersma R.D., de Weger R.A., van Diest P.J. ESR1 amplification is rare in breast cancer and is associated with high grade and high proliferation: a multiplex ligation-dependent probe amplification study. Cell Oncol. (Dordr.) 2011, 34:489-494.
45. Gelsi-Boyer V., Orsetti B., Cervera N., Finetti P., Sircoulomb F., Rouge C., Lasorsa L., Letessier A., Ginestier C., Monville F., Esteyries S., Adelaide J., Esterni B., Henry C., Ethier S.P., Bibeau F., Mozziconacci M.J., Charafe-Jauffret E., Jacquemier J., Bertucci F., Birnbaum D., Theillet C., Chaffanet M. Comprehensive profiling of 8p11-12 amplification in breast cancer. Mol. Cancer Res. 2005, 3:655-667.
46. Jang M.H., Kim E.J., Choi Y., Lee H.E., Kim Y.J., Kim J.H., Kang E., Kim S.W., Kim I.A., Park S.Y. FGFR1 is amplified during the progression of in situ to invasive breast carcinoma. Breast Cancer Res. 2012, 14:R115.
47. Turner N., Pearson A., Sharpe R., Lambros M., Geyer F., Lopez-Garcia M.A., Natrajan R., Marchio C., Iorns E., Mackay A., Gillett C., Grigoriadis A., Tutt A., Reis-Filho J.S., Ashworth A. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 2010, 70:2085-2094.
48. Smoter M., Bodnar L., Duchnowska R., Stec R., Grala B., Szczylik C. The role of Tau protein in resistance to paclitaxel. Cancer Chemother. Pharmacol. 2011, 68:553-557.
49. Matrone M.A., Whipple R.A., Thompson K., Cho E.H., Vitolo M.I., Balzer E.M., Yoon J.R., Ioffe O.B., Tuttle K.C., Tan M., Martin S.S. Metastatic breast tumors express increased tau, which promotes microtentacle formation and the reattachment of detached breast tumor cells. Oncogene 2010, 29:3217-3227.
50. Baquero M.T., Lostritto K., Gustavson M.D., Bassi K.A., Appia F., Camp R.L., Molinaro A.M., Harris L.N., Rimm D.L. Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts. Breast Cancer Res. 2011, 13:R85.